{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:35:56Z","timestamp":1787020556735,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07623-8","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:46:53Z","timestamp":1768204013000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Venetoclax induces mitochondrial apoptosis and autophagy to overcome arsenic trioxide resistance in acute promyelocytic leukemia"],"prefix":"10.1186","volume":"24","author":[{"given":"Deepshikha","family":"Dutta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Maity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Gera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasmukh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Rajpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingaraj","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Punatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avik","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezhilarasi","family":"Chendamarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Balasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Gota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Khattry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Sengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9580-5183","authenticated-orcid":false,"given":"Syed K.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"issue":"1","key":"7623_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.beha.2014.04.006","volume":"27","author":"F Lo-Coco","year":"2014","unstructured":"Lo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2014;27(1):3\u20139.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"15","key":"7623_CR2","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","volume":"133","author":"MA Sanz","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS, Estey EH, Lowenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630\u201343.","journal-title":"Blood"},{"issue":"15","key":"7623_CR3","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1182\/blood-2011-11-393264","volume":"119","author":"E Chendamarai","year":"2012","unstructured":"Chendamarai E, Balasubramanian P, George B, Viswabandya A, Abraham A, Ahmed R, et al. Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy. Blood. 2012;119(15):3413\u201319.","journal-title":"Blood"},{"issue":"6","key":"7623_CR4","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1182\/blood-2011-01-329433","volume":"118","author":"E Goto","year":"2011","unstructured":"Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood. 2011;118(6):1600\u201309.","journal-title":"Blood"},{"issue":"19","key":"7623_CR5","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1056\/NEJMc1316382","volume":"370","author":"HH Zhu","year":"2014","unstructured":"Zhu HH, Qin YZ, Huang XJ. Resistance to arsenic therapy in acute promyelocytic leukemia. N Engl J Med. 2014;370(19):1864\u201366.","journal-title":"N Engl J Med"},{"issue":"2","key":"7623_CR6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1182\/bloodadvances.2021005300","volume":"6","author":"N Balasundaram","year":"2022","unstructured":"Balasundaram N, Ganesan S, Chendamarai E, Palani HK, Venkatraman A, Alex AA, et al. Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia. Blood Adv. 2022;6(2):652\u201363.","journal-title":"Blood Adv"},{"key":"7623_CR7","doi-asserted-by":"crossref","unstructured":"Noguera NI, Catalano G, Banella C, Divona M, Faraoni I, Ottone T, et al. Acute promyelocytic leukemia: update on the mechanisms of Leukemogenesis, resistance and on innovative treatment strategies. Cancers (Basel). 2019;11(10).","DOI":"10.3390\/cancers11101591"},{"issue":"5","key":"7623_CR8","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/bjh.19119","volume":"203","author":"P Qi","year":"2023","unstructured":"Qi P, Wang L, Li H, Wu Y, Fan J, Huang P, et al. Venetoclax as a cytoreduction therapy for acute promyelocytic leukaemia: a single-centre experience. Br J Haematol. 2023;203(5):892\u201395.","journal-title":"Br J Haematol"},{"key":"7623_CR9","doi-asserted-by":"crossref","unstructured":"Giansanti M, Ottone T, Travaglini S, Voso MT, Graziani G, Faraoni I. Combination treatment of resistant acute promyelocytic leukemia cells with arsenic trioxide and anti-apoptotic gene inhibitors. Pharmaceuticals (Basel). 2024;17(11).","DOI":"10.3390\/ph17111529"},{"issue":"12","key":"7623_CR10","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1158\/2159-8290.CD-23-0453","volume":"13","author":"P Bercier","year":"2023","unstructured":"Bercier P, Wang QQ, Zang N, Zhang J, Yang C, Maimaitiyiming Y, et al. Structural basis of PML-RARA oncoprotein Targeting by arsenic unravels a cysteine rheostat controlling PML body assembly and function. Cancer Discov. 2023;13(12):2548\u201365.","journal-title":"Cancer Discov"},{"issue":"3","key":"7623_CR11","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1182\/blood.V88.3.1052.1052","volume":"88","author":"GQ Chen","year":"1996","unstructured":"Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha\/PML proteins. Blood. 1996;88(3):1052\u201361.","journal-title":"Blood"},{"issue":"7","key":"7623_CR12","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/sj.leu.2402983","volume":"17","author":"X Cai","year":"2003","unstructured":"Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, et al. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia. 2003;17(7):1333\u201337.","journal-title":"Leukemia"},{"issue":"1","key":"7623_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1756-9966-33-42","volume":"33","author":"S Kumar","year":"2014","unstructured":"Kumar S, Yedjou CG, Tchounwou PB. Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells. J Exp Clin Cancer Res. 2014;33(1):42.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"7623_CR14","first-page":"714","volume":"5","author":"L Yang","year":"2015","unstructured":"Yang L, Chai W, Wang Y, Cao L, Xie M, Yang M, et al. Reactive oxygen species regulate the differentiation of acute promyelocytic leukemia cells through HMGB1-mediated autophagy. Am J Cancer Res. 2015;5(2):714\u201325.","journal-title":"Am J Cancer Res"},{"issue":"13","key":"7623_CR15","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood-2010-01-261040","volume":"116","author":"P Isakson","year":"2010","unstructured":"Isakson P, Bjoras M, Boe SO, Simonsen A. Autophagy contributes to therapy-induced degradation of the PML\/RARA oncoprotein. Blood. 2010;116(13):2324\u201331.","journal-title":"Blood"},{"issue":"2","key":"7623_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41419-017-0018-3","volume":"9","author":"T Li","year":"2018","unstructured":"Li T, Ma R, Zhang Y, Mo H, Yang X, Hu S, et al. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy. Cell Death Dis. 2018;9(2):75.","journal-title":"Cell Death Dis"},{"issue":"7","key":"7623_CR17","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Glytsou C, Zhou H, Narang S, Reyna DE, Lopez A, et al. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov. 2019;9(7):890\u2013909.","journal-title":"Cancer Discov"},{"issue":"12","key":"7623_CR18","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","volume":"24","author":"DA Pollyea","year":"2018","unstructured":"Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24(12):1859\u201366.","journal-title":"Nat Med"},{"issue":"4","key":"7623_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Guieze","year":"2019","unstructured":"Guieze R, Liu VM, Rosebrock D, Jourdain AA, Hernandez-Sanchez M, Martinez Zurita A, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36(4):369\u201384 e13.","journal-title":"Cancer Cell"},{"key":"7623_CR20","doi-asserted-by":"crossref","unstructured":"Sharon D, Cathelin S, Mirali S, Di Trani JM, Yanofsky DJ, Keon KA, et al. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Sci Transl Med. 2019;11(516).","DOI":"10.1126\/scitranslmed.aax2863"},{"key":"7623_CR21","doi-asserted-by":"crossref","unstructured":"Avsec D, Jakos Djordjevic AT, Kanduser M, Podgornik H, Skerget M, Mlinaric-Rascan I. Targeting autophagy triggers apoptosis and complements the action of venetoclax in chronic lymphocytic leukemia cells. Cancers (basel). 2021;13(18).","DOI":"10.3390\/cancers13184557"},{"issue":"9","key":"7623_CR22","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1021\/acsmedchemlett.2c00309","volume":"13","author":"X Dong","year":"2022","unstructured":"Dong X, Liang Q, Pan YZ, Wang X, Kuo YC, Chiang WC, et al. Novel Bcl-2 inhibitors selectively disrupt the autophagy-specific Bcl-2-Beclin 1 protein-protein interaction. ACS Med Chem Lett. 2022;13(9):1510\u201316.","journal-title":"ACS Med Chem Lett"},{"issue":"10","key":"7623_CR23","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1038\/sj.emboj.7601689","volume":"26","author":"MC Maiuri","year":"2007","unstructured":"Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P, et al. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J. 2007;26(10):2527\u201339.","journal-title":"Embo J"},{"issue":"48","key":"7623_CR24","doi-asserted-by":"publisher","first-page":"e28076","DOI":"10.1097\/MD.0000000000028076","volume":"100","author":"Y Li","year":"2021","unstructured":"Li Y, Yu J, Xu Q, Zhang K. Relapsed\/Refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: a case report. Med (baltim). 2021;100(48):e28076.","journal-title":"Med (baltim)"},{"issue":"7","key":"7623_CR25","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/leu.2014.72","volume":"28","author":"X Niu","year":"2014","unstructured":"Niu X, Wang G, Wang Y, Caldwell JT, Edwards H, Xie C, et al. Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia. 2014;28(7):1557\u201360.","journal-title":"Leukemia"},{"issue":"5","key":"7623_CR26","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1111\/bjh.18061","volume":"197","author":"QQ Wang","year":"2022","unstructured":"Wang QQ, Wang HF, Zhao JZ, Naranmandura H, Jin J, Zhu HH. Venetoclax for arsenic-resistant acute promyelocytic leukaemia. Br J Haematol. 2022;197(5):e58\u201360.","journal-title":"Br J Haematol"},{"issue":"4","key":"7623_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/mc.23671","volume":"63","author":"J Xu","year":"2024","unstructured":"Xu J, Li H, Wang Z, Wang M, Li Q, Hang X, et al. Venetoclax overcomes resistance to all-trans retinoic acid in a variant acute promyelocytic leukemia with TNRC18: rara fusion. Mol Carcinog. 2024;63(4):553\u201357.","journal-title":"Mol Carcinog"},{"issue":"12","key":"7623_CR28","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against Cancer program. Leukemia. 2003;17(12):2318\u201357.","journal-title":"Leukemia"},{"issue":"2","key":"7623_CR29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440\u201346.","journal-title":"Cancer Res"},{"issue":"6","key":"7623_CR30","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1073\/pnas.94.6.2551","volume":"94","author":"D Brown","year":"1997","unstructured":"Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1997;94(6):2551\u201356.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7623_CR31","doi-asserted-by":"publisher","first-page":"114253","DOI":"10.1016\/j.bcp.2020.114253","volume":"182","author":"JL Carter","year":"2020","unstructured":"Carter JL, Hege K, Kalpage HA, Edwards H, Huttemann M, Taub JW, et al. Targeting mitochondrial respiration for the treatment of acute myeloid leukemia. Biochem Pharmacol. 2020;182:114253.","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"7623_CR32","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1182\/bloodadvances.2020002666","volume":"5","author":"KM Dykstra","year":"2021","unstructured":"Dykstra KM, Fay HRS, Massey AC, Yang N, Johnson M, Portwood S, et al. Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis. Blood Adv. 2021;5(8):2087\u2013100.","journal-title":"Blood Adv"},{"issue":"8","key":"7623_CR33","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1074\/jbc.M203080200","volume":"278","author":"G Manfredi","year":"2003","unstructured":"Manfredi G, Kwong JQ, Oca-Cossio JA, Woischnik M, Gajewski CD, Martushova K, et al. BCL-2 improves oxidative phosphorylation and modulates adenine nucleotide translocation in mitochondria of cells harboring mutant mtDNA. J Biol Chem. 2003;278(8):5639\u201345.","journal-title":"J Biol Chem"},{"issue":"3","key":"7623_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cmet.2020.07.009","volume":"32","author":"van Gastel N","year":"2020","unstructured":"van Gastel N, Spinelli JB, Sharda A, Schajnovitz A, Baryawno N, Rhee C, et al. Induction of a timed metabolic collapse to overcome Cancer chemoresistance. Cell Metab. 2020;32(3):391\u2013403 e6.","journal-title":"Cell Metab"},{"issue":"8","key":"7623_CR35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41419-019-1851-3","volume":"10","author":"SB Panina","year":"2019","unstructured":"Panina SB, Baran N, Brasil da Costa FH, Konopleva M, Kirienko NV. A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugs. Cell Death Dis. 2019;10(8):617.","journal-title":"Cell Death Dis"},{"issue":"11","key":"7623_CR36","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1038\/leu.2016.227","volume":"30","author":"S Ganesan","year":"2016","unstructured":"Ganesan S, Alex AA, Chendamarai E, Balasundaram N, Palani HK, David S, et al. Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 2016;30(11):2169\u201378.","journal-title":"Leukemia"},{"issue":"1","key":"7623_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ccr.2010.06.003","volume":"18","author":"M Jeanne","year":"2010","unstructured":"Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, et al. PML\/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 2010;18(1):88\u201398.","journal-title":"Cancer Cell"},{"issue":"2","key":"7623_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1182\/blood-2015-04-637678","volume":"127","author":"J Liu","year":"2016","unstructured":"Liu J, Zhu HH, Jiang H, Jiang Q, Huang XJ. Varying responses of PML-RARA with different genetic mutations to arsenic trioxide. Blood. 2016;127(2):243\u201350.","journal-title":"Blood"},{"issue":"10","key":"7623_CR39","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase ii study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106\u201317.","journal-title":"Cancer Discov"},{"issue":"3","key":"7623_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell STEM Cell. 2013;12(3):329\u201341.","journal-title":"Cell STEM Cell"},{"issue":"2","key":"7623_CR41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202\u201308.","journal-title":"Nat Med"},{"key":"7623_CR42","doi-asserted-by":"crossref","unstructured":"Hoang DH, Buettner R, Valerio M, Ghoda L, Zhang B, Kuo YH, et al. Arsenic trioxide and venetoclax synergize against AML progenitors by ROS induction and inhibition of Nrf2 activation. Int J Mol Sci. 2022;23(12).","DOI":"10.3390\/ijms23126568"},{"key":"7623_CR43","first-page":"100482","volume":"22","author":"W Li","year":"2024","unstructured":"Li W, Li H, Chen X, Zheng Y. Venetoclax for an ATRA and ATO resistance acute promyelocytic leukemia patient with TNRC18: rara fusion gene. Leuk Res Rep. 2024;22:100482.","journal-title":"Leuk Res Rep"},{"key":"7623_CR44","doi-asserted-by":"publisher","first-page":"828852","DOI":"10.3389\/fonc.2022.828852","volume":"12","author":"B Song","year":"2022","unstructured":"Song B, Wang X, Kong X, Wang M, Yao L, Shen H, et al. Clinical response to venetoclax and decitabine in acute promyelocytic leukemia with a Novel RARA-THRAP3 fusion: a case report. Front Oncol. 2022;12:828852.","journal-title":"Front Oncol"},{"issue":"8","key":"7623_CR45","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41419-020-02867-2","volume":"11","author":"A Roca-Portoles","year":"2020","unstructured":"Roca-Portoles A, Rodriguez-Blanco G, Sumpton D, Cloix C, Mullin M, Mackay GM, et al. Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition. Cell Death Dis. 2020;11(8):616.","journal-title":"Cell Death Dis"},{"issue":"4","key":"7623_CR46","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1089\/ars.2008.2270","volume":"11","author":"MB Azad","year":"2009","unstructured":"Azad MB, Chen Y, Gibson SB. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal. 2009;11(4):777\u201390.","journal-title":"Antioxid Redox Signal"},{"issue":"7","key":"7623_CR47","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/cdd.2009.49","volume":"16","author":"Y Chen","year":"2009","unstructured":"Chen Y, Azad MB, Gibson SB. Superoxide is the major reactive oxygen species regulating autophagy. Cell Death Differ. 2009;16(7):1040\u201352.","journal-title":"Cell Death Differ"},{"issue":"9","key":"7623_CR48","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tcb.2007.07.009","volume":"17","author":"R Scherz-Shouval","year":"2007","unstructured":"Scherz-Shouval R, Elazar Z. ROS, mitochondria and the regulation of autophagy. Trends Cell Biol. 2007;17(9):422\u201327.","journal-title":"Trends Cell Biol"},{"issue":"3","key":"7623_CR49","doi-asserted-by":"publisher","first-page":"M111 014035","DOI":"10.1074\/mcp.M111.014035","volume":"11","author":"J Dengjel","year":"2012","unstructured":"Dengjel J, Hoyer-Hansen M, Nielsen MO, Eisenberg T, Harder LM, Schandorff S, et al. Identification of autophagosome-associated proteins and regulators by quantitative proteomic analysis and genetic screens. Mol Cell Proteomics. 2012;11(3):M111 014035.","journal-title":"Mol Cell Proteomics"},{"issue":"21","key":"7623_CR50","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1038\/onc.2009.60","volume":"28","author":"IA Ciechomska","year":"2009","unstructured":"Ciechomska IA, Goemans GC, Skepper JN, Tolkovsky AM. Bcl-2 complexed with Beclin-1 maintains full anti-apoptotic function. Oncogene. 2009;28(21):2128\u201341.","journal-title":"Oncogene"},{"issue":"6","key":"7623_CR51","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2005.07.002","volume":"122","author":"S Pattingre","year":"2005","unstructured":"Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122(6):927\u201339.","journal-title":"Cell"},{"issue":"2","key":"7623_CR52","doi-asserted-by":"publisher","first-page":"e 1088","DOI":"10.1038\/cddis.2014.59","volume":"5","author":"Y Feng","year":"2014","unstructured":"Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, et al. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 2014;5(2):e1088.","journal-title":"Cell Death Dis"},{"issue":"2003","key":"7623_CR53","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1182\/blood-2002-08-2474","volume":"101,9","author":"Akira Kawasaki","year":"2003","unstructured":"Kawasaki A, et al. Opposing effects of PML and PML\/RAR alpha on STAT3 activity. Blood 2003;101(9):3668\u201373. https:\/\/doi.org\/10.1182\/blood-2002-08-2474.","journal-title":"Blood"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07623-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07623-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07623-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:54:56Z","timestamp":1768474496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07623-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7623"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07623-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IECIII: ECR\/149\/Inst\/MH\/2013 approved the study with the reference letter number IEC outward 219\/2019 dated 24\/05\/2019 (study approval reference number: 900,535\/2019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All NOD\/SCID mice experiments were conducted in accordance with guidelines approved by animal ethics committee of Tata Memorial Centre, Mumbai (study reference approval number IAEC\/14\/2019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institute Animal Ethics Committee"}},{"value":"All patients and healthy donors included in this study provided written informed consent following the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"During the preparation of this work we used Grammarly in order to improve the readability. After using this tool, we reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}},{"value":"The authors declare no potential conflict of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}